期刊
FUTURE MEDICINAL CHEMISTRY
卷 8, 期 12, 页码 1485-1501出版社
Newlands Press Ltd
DOI: 10.4155/fmc-2016-0050
关键词
ABC and MFS transporters; antifungal drug resistance; azole; chemosensitzation; heterologous expression; high-throughput screen
资金
- NIH [R01-DE016855-01, R03-MH087406-1A1, U54 MH074425/MH086490]
- Royal Society of New Zealand Marsden Fund [UOO1305]
- Health Research Council of New Zealand's International Investment Opportunities Fund [IIOF 09_04]
- Health Research Council of New Zealand
- University of Otago
Resistance to antifungal drugs is an increasingly significant clinical problem. The most common antifungal resistance encountered is efflux pump-mediated resistance of Candida species to azole drugs. One approach to overcome this resistance is to inhibit the pumps and chemosensitize resistant strains to azole drugs. Drug discovery targeting fungal efflux pumps could thus result in the development of azole-enhancing combination therapy. Heterologous expression of fungal efflux pumps in Saccharomyces cerevisiae provides a versatile system for screening for pump inhibitors. Fungal efflux pumps transport a range of xenobiotics including fluorescent compounds. This enables the use of fluorescence-based detection, as well as growth inhibition assays, in screens to discover compounds targeting efflux-mediated antifungal drug resistance. A variety of medium-and high-throughput screens have been used to identify a number of chemical entities that inhibit fungal efflux pumps.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据